Compare SPOK & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPOK | ACIU |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.7M | 221.9M |
| IPO Year | 2004 | 2015 |
| Metric | SPOK | ACIU |
|---|---|---|
| Price | $10.66 | $2.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $14.00 | $10.00 |
| AVG Volume (30 Days) | 160.8K | ★ 235.1K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | ★ 11.31% | N/A |
| EPS Growth | ★ 2.74 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $139,708,000.00 | N/A |
| Revenue This Year | $1.70 | $706.75 |
| Revenue Next Year | N/A | $321.13 |
| P/E Ratio | $116.78 | ★ N/A |
| Revenue Growth | ★ 1.49 | N/A |
| 52 Week Low | $9.95 | $2.03 |
| 52 Week High | $19.31 | $4.00 |
| Indicator | SPOK | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 45.22 | N/A |
| Support Level | $10.26 | N/A |
| Resistance Level | $10.78 | N/A |
| Average True Range (ATR) | 0.19 | 0.00 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 30.58 | 0.00 |
Spok Holdings Inc is a provider of healthcare communications. The company delivers clinical communication and collaboration solutions to help protect the health, well-being, and safety of people in the United States and abroad, on a limited basis, in Europe, Canada, Australia, Asia, and the Middle East. The company develops, sells, and supports enterprise-wide systems principally for healthcare and other organizations needing to automate, centralize, and standardize their approach to clinical and critical communications. The company offers its services and products to three market segments: healthcare, government, and large enterprise, with a greater emphasis on the healthcare market segment. Geographically, the company generates the majority of its revenue from the United States.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.